Recent Corporate Highlights
- A Phase 1 clinical trial was initiated for KB004.
- KaloBios partnered with Sanofi Pasteur for KB001A in hospital indications.
- Two Phase 1/2 trials for KB001 (anti-Pseudomonas antibody) were completed; one in cystic fibrosis and another in intensive care patients on mechanical ventilation.
- A multi-dose safety trial was completed for KB003.
- Three Phase 1/2 trials for KB002 (a prototype anti-GM-CSF antibody) were completed, including trials in asthma and rheumatoid arthritis.